HSBC Holdings PLC (HSBC, Financial), Walgreens Boots Alliance Inc. (WBA, Financial), DuPont de Nemours Inc. (DD, Financial) and Gilead Sciences Inc. (GILD, Financial) have declined to their three-year lows.
HSBC Holdings declined to $36.29
The price of HSBC Holdings shares declined to $36.29 on Jan. 31, which is only 2.6% above the three-year low of $35.36
HSBC Holdings is a British international financial services holding company. As of December 2018, it is the largest bank in Europe with total assets of $2.558 trillion. The company has around 3,900 offices in 67 countries and around 38 million customers. It is also a component of the FTSE 100.
The company has a market cap of $147.43 billion; its shares were traded around $36.29 with a price-earnings ratio of 25.07 and a price-sales ratio of 4.34. The trailing 12-month dividend yield is 7.01%. The forward dividend yield is 5.40%.
On Dec. 9, HSBC announced significant changes to its senior management team. Pam Kaur, head of Wholesale Market and Credit Risk, was appointed as group chief risk officer effective Jan. 1. Marc Moses, an executive director of the company, assisted with a handover of his responsibilities before stepping down from the board of directors and the role of group chief risk officer on Dec. 31. Moses will continue to provide support to the group chief executive until he formally retires on Dec. 9, 2020.
Walgreens Boots Alliance declined to $50.85
The price of Walgreens Boots Alliance shares have declined to $50.85 on Jan. 31, which is only 3.6% above the three-year low of $49.03.
Walgreens is an American holding company that owns Walgreens, Boots, and other pharmaceutical manufacturing, wholesale and distribution companies.
Walgreens has a market cap of $45.05 billion; its shares were traded around $50.85 with a price-earnings ratio of 12.48 and a price-sales ratio of 0.34. The trailing 12-month dividend yield is 3.53%. The forward dividend yield is 3.52%. The company had an annual average earnings growth of 5.90% over the past 10 years.
On Jan. 30, Walgreens announced that its board of directors had declared a quarterly dividend of 45.75 cents per share, representing an increase of 4% from the prior-year quarter. The dividend will be payable on March 12 to shareholders of record at the close of business on Feb. 19.
DuPont de Nemours declined to $51.18
The price of DuPont de Nemours shares declined to $51.18 on Jan. 31, which is only 0.5% above the three-year low of $50.94.
The international chemical company that was formed by the merger of Dow Chemical and DuPont in 2017. Prior to the spinoff of Dow Inc. and Corteva, the company was the world’s largest chemical company in terms of sales. The company is a component of the S&P 100.
DuPont De Nemours has a market cap of $37.91 billion; its shares were traded around $51.18 with a price-earnings ratio of 48.29 and a price-sales ratio of 0.39. The trailing 12-month dividend yield is 4.22%. The forward dividend yield is 2.28%. The company had an annual average earnings growth of 2.10% over the past 10 years.
On Jan. 30, DuPont reported fourth-quarter and full-year 2019 financial results. Net sales for the quarter were $5.2 billion, a decrease of 5% compared to a year ago. GAAP earnings per share were 24 cents for the quarter, while adjusted earnings per share were 95 cents. GAAP income totaled $191 million, compared to $310 million during the prior-year quarter.
Gilead Sciences declined to $63.20
The price of Gilead Sciences shares declined to $63.20 on Jan. 31, which is only 4.6% above the three-year low of $60.32.
Gilead Sciences is an American pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza.
The company has a market cap of $79.96 billion; its shares were traded around $63.20 with a price-earnings ratio of 30.26 and a price-sales ratio of 3.60. The trailing 12-month dividend yield is 4.01%. The forward dividend yield is 3.94%. Gilead Sciences had an annual average earnings growth of 26.10% over the past 10 years.
On Jan. 9, Gilead Sciences announced that the company has licensed the Rockefeller University’s portfolio of broadly neutralizing antibodies against HIV, including two clinical-stage agents: 3BNC117 and 10-1074. These agents have potential for long-acting HIV therapies for both treatment and prevention.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here
